Table 2. Particulated rE induced a balanced serotype specific tetravalent neutralizing antibody response in mice.
| TR (rE DV1-4) | |||||
| Serotype |
Undepl. (Neut50) |
Ctrl depl. (Neut50) | TS depl. (Neut50) | CR depl. (Neut50) |
TS neut |
| DV1 | 2398 | 912 | 50 | 53 | 6.1% |
| DV2 | 7244 | 3715 | 50 | 1819 | 49.6% |
| DV3 | 10232 | 4466 | 50 | 1891 | 41.2% |
| DV4 | 1778 | 1513 | 50 | 630 | 43.1% |
|
TNR (NP-DV1 + NP-DV2 + NP-DV3 + NP-DV4) | |||||
| Serotype |
Undepl. (Neut50) |
Ctrl depl. (Neut50) | TS depl. (Neut50) | CR depl. (Neut50) |
TS neut |
| DV1 | 1995 | 1174 | 50 | 257 | 22.8% |
| DV2 | 6918 | 2691 | 50 | 1000 | 37.8% |
| DV3 | 3090 | 2454 | 50 | 1318 | 54.8% |
| DV4 | 1258 | 562 | 50 | 501 | 97.8% |
The proportions of serotype-specific and cross-reactive neutralizing antibody titers per DENV serotype in sera of mice immunized with tetravalent vaccine formulations were evaluated using a DENV serum depletion assay. Serum was incubated with magnetic beads coated with rE of DENV1, 2, 3 or 4 and serotype specific neutralizing IgG titers were determined against all 4 rE serotypes. The neutralizing capacity of undepleted (Undepl.), handling control sera (Ctrl depl.), serotype specific depleted (TS depl.) and cross-reactive depleted (CR depl.) was expressed as Neut50 values and used to determine the percentage of serotype specific neutralizing antibodies (TS neut).